Human Longevity, Inc. Pledges Bold $1 Million for Each Qualified Member Against Prostate Cancer
SOUTH SAN FRANCISCO, Calif., March 20, 2025 /PRNewswire/ -- Human Longevity, Inc., a leader in precision medicine and proactive healthcare, is proud to announce a groundbreaking commitment in the fight against prostate cancer. In a bold move that underscores its dedication to advancing cancer prevention and patient outcomes, Human Longevity is pledging up to $1 million for each qualified member diagnosed with late-stage prostate cancer for treatment while under the company's longevity programs.
Pioneering Early Detection
Over the past decade, by caring for more than 5,000 men and leveraging genomics, advanced imaging, and comprehensive longitudinal blood biomarker tracking, Human Longevity has developed what it believes to be the most advanced algorithm for early prostate cancer detection through its Executive Health Program and other 100+ Longevity Programs.
Based on extensive experience in detecting early-stage prostate cancer, Human Longevity is confident that the majority of future Human Longevity members will discover their prostate cancer at a curable stage. However, in rare cases where a diagnosis is made at a late stage, Human Longevity now has an advanced solution in place—this $1 million pledge ensures that no member faces this battle alone.
Through its vast network of top urologists, oncologists, and researchers from world-class institutions, Human Longevity's $1 million pledge ensures that members diagnosed with late-stage prostate cancer receive the best possible care—without financial or logistical barriers.
How the Initiative Works
To participate in the Prostate Cancer Screening Commitment, individuals must be enrolled in Human Longevity's Executive Health Program and other 100+ Longevity Programs. Unlike most executive health programs, Human Longevity's unique programs include:
- Whole genome sequencing
- Whole-body MRI, including a dedicated prostate MRI
- Long-term multi-plexed blood biomarker tracking
By enrolling, members gain access to cutting-edge early cancer detection methods, significantly reducing the risk of late-stage prostate cancer diagnosis.
A New Era of Cancer Prevention
Prostate cancer is the second most common cancer among men in the United States, with over 200,000 new cases diagnosed annually. In response, Human Longevity, Inc. continues to lead the way in data-driven, preventative cancer care, using the latest advancements in genomics, AI, and medical technology.
Beyond helping individuals, this initiative accelerates medical advancements in prostate cancer detection and treatment. Human Longevity continuously enhances its algorithm for detecting prostate cancer by using real-world data and learning from every case through its Executive Health Program. This pledge is more than a safety net—it is a strategic investment in a future where prostate cancer is caught early and treated effectively.
About Human Longevity, Inc.
Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health Program and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges.
Contact
SOURCE Human Longevity, Inc.
Share this article